Overexpression of is Associated with Poor Prognosis and Tumor Progression of Breast Cancer in Chinese Females

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 May 2

PMID 29713186

Citations 13

Authors

Yixiang Huang

Wei Jian

Junyong Zhao

Gang Wang

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer represents a serious health issue among females. has been identified as an oncogene in human cancers. This study sought to assess the prognostic value and the biologic function of in breast cancer patients.

Methods: Expression of in breast cancer tissues and cells was evaluated by quantitative real-time polymerase chain reaction. Kaplan-Meier survival analysis and Cox regression assay were conducted to explore the prognostic significance of . Cell experiments were performed to investigate the effects of on the biologic behaviors of breast cancer cells.

Results: Expression of was significantly upregulated in both cancerous tissues and cells compared with the normal controls (all <0.05). Overexpression of was correlated with lymph node metastasis (=0.021) and TNM stage (=0.004). Patients with high had poor overall survival compared to those with low levels of (log-rank <0.05). Elevated was found to be an independent prognostic factor for the patients (hazard ratio=2.996, 95% CI=1.611-5.572, =0.001). According to the cell experiments, tumor cell proliferation, migration and invasion were suppressed by knockdown of .

Conclusion: All data demonstrated that overexpression of serves as a prognostic biomarker and may be involved in the tumor progression of breast cancer.

Citing Articles

Association of germline variants with somatic variants in breast tumors in a genome-wide study.

Tjader N, Beer A, Ramroop J, Tai M, Ping J, Gandhi T medRxiv. 2023; .

PMID: 38106140 PMC: 10723566. DOI: 10.1101/2023.12.06.23299442.

HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors.

Das T, Khatun S, Jha T, Gayen S Mini Rev Med Chem. 2023; 24(7):767-784.

PMID: 37818566 DOI: 10.2174/0113895575267301230919165827.

Integrated Analysis Reveals the Potential Significance of HDAC Family Genes in Lung Adenocarcinoma.

Song C, Lin W, Meng H, Li N, Geng Q Front Genet. 2022; 13:862977.

PMID: 36072664 PMC: 9441483. DOI: 10.3389/fgene.2022.862977.

Comprehensive Analysis of the Differential Expression and Prognostic Value of Histone Deacetylases in Glioma.

Li J, Yan X, Liang C, Chen H, Liu M, Wu Z Front Cell Dev Biol. 2022; 10:840759.

PMID: 35359455 PMC: 8961059. DOI: 10.3389/fcell.2022.840759.

HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway.

Guo K, Ma Z, Zhang Y, Han L, Shao C, Feng Y J Exp Clin Cancer Res. 2022; 41(1):91.

PMID: 35277183 PMC: 8915541. DOI: 10.1186/s13046-022-02266-9.

References

Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y . HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004; 10(20):6962-8. DOI: 10.1158/1078-0432.CCR-04-0455. View

Chen S, Ibrahim N, Yan Y, Wong S, Wang H, Wong F . Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Cancer. 2015; 121(22):3965-74. DOI: 10.1002/cncr.29565. View

Eom M, Oh S, Lkhagvadorj S, Han A, Park K . HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor. Korean J Pathol. 2012; 46(4):311-7. PMC: 3479820. DOI: 10.4132/KoreanJPathol.2012.46.4.311. View

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

West A, Johnstone R . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-9. PMC: 3871231. DOI: 10.1172/JCI69738. View

Fu D, Tan H, Wei J, Zhu C, Jiang J, Zhu Y . Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer. Tumour Biol. 2015; 36(10):8025-34. DOI: 10.1007/s13277-015-3547-3. View

Rahimzadeh M, Baghestani A, Gohari M, Pourhoseingholi M . Estimation of the cure rate in Iranian breast cancer patients. Asian Pac J Cancer Prev. 2014; 15(12):4839-42. DOI: 10.7314/apjcp.2014.15.12.4839. View

Ooi J, Tuano N, Rafehi H, Gao X, Ziemann M, Du X . HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. Epigenetics. 2015; 10(5):418-30. PMC: 4622459. DOI: 10.1080/15592294.2015.1024406. View

Liao M, Chen S, Chen S, Lin Y, Chen M, Wang C . Change and predictors of symptom distress in breast cancer patients following the first 4 months after diagnosis. J Formos Med Assoc. 2013; 114(3):246-53. DOI: 10.1016/j.jfma.2013.06.009. View

10.

Spaks A, Svirina D, Spaka I, Jaunalksne I, Breiva D, Tracums I . CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment. Biomarkers. 2016; 21(5):474-8. DOI: 10.3109/1354750X.2016.1172111. View

11.

Jovanovic J, Ronneberg J, Tost J, Kristensen V . The epigenetics of breast cancer. Mol Oncol. 2010; 4(3):242-54. PMC: 5527941. DOI: 10.1016/j.molonc.2010.04.002. View

12.

Jerzak K, Cockburn J, Pond G, Pritchard K, Narod S, Dhesy-Thind S . Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Res Treat. 2014; 149(1):293-301. DOI: 10.1007/s10549-014-3235-9. View

13.

Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P . HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res. 2010; 16(12):3240-52. DOI: 10.1158/1078-0432.CCR-10-0395. View

14.

Hsieh C, Ma H, Su C, Chang Y, Hung W, Ho Y . Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer. Life Sci. 2016; 151:7-14. DOI: 10.1016/j.lfs.2016.02.092. View

15.

Okudela K, Mitsui H, Suzuki T, Woo T, Tateishi Y, Umeda S . Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis. Int J Clin Exp Pathol. 2014; 7(1):213-20. PMC: 3885475. View

16.

Gong F, Miller K . Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat Res. 2013; 750(1-2):23-30. DOI: 10.1016/j.mrfmmm.2013.07.002. View

17.

Hoang J, Baron S, Volle D, Lobaccaro J, Trousson A . Lipids, LXRs and prostate cancer: are HDACs a new link?. Biochem Pharmacol. 2013; 86(1):168-74. DOI: 10.1016/j.bcp.2013.04.005. View

18.

Matsuda K, Mori H, Kawata M . Epigenetic mechanisms are involved in sexual differentiation of the brain. Rev Endocr Metab Disord. 2012; 13(3):163-71. DOI: 10.1007/s11154-012-9202-z. View

19.

Zheng R, Pan L, Gao J, Ye X, Chen L, Zhang X . Prognostic value of miR-106b expression in breast cancer patients. J Surg Res. 2015; 195(1):158-65. DOI: 10.1016/j.jss.2014.12.035. View

20.

Seber S, Solmaz D, Yetisyigit T . Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting. Onco Targets Ther. 2016; 9:4929-35. PMC: 4984830. DOI: 10.2147/OTT.S108968. View